DELRAY BEACH, Fla., Oct. 20, 2026 /PRNewswire/ — According to MarketsandMarkets™, the Lipid Nanoparticles Market is projected to reach USD 395.0 million by 2031, up from USD 298.8 million in 2026, at a CAGR of 5.7%. In parallel, the LNP services market is projected to reach USD 309.2 million by 2031, up from USD 161.0 million in 2026, at a CAGR of 13.9% during the forecast period.
Browse 300 market data Tables and 53 Figures spread through 316 Pages and in-depth TOC on “Lipid Nanoparticles Market – Global Forecast to 2031”
Lipid Nanoparticles Market Size & Forecast:
- Market Size Available for Years: 2026–2031
- 2026 Market Size: USD 298.8 million
- 2031 Projected Market Size: USD 395.0 million
- CAGR (2026–2031): 5.7%
Lipid Nanoparticles Market Trends & Insights:
- The North American LNP raw materials and services market accounted for the largest share in 2025.
- By product, the ionizable lipids segment accounted for the largest share (6.20%) of the LNP raw materials market in 2025.
- By molecule type, the mRNA segment is expected to post the highest CAGR of 5.8% over the forecast period.
- By end user, pharmaceutical & biotechnology companies accounted for the largest share (41.7%) of the LNP raw materials market in 2025.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=70136984
Growth in the LNP raw materials and services market is driven by the expanding development and commercialization of mRNA vaccines and therapeutics, siRNA medicines, gene-editing therapies, and other nucleic acid-based products. Increasing demand for high-purity pharmaceutical-grade lipids, scalable nanoparticle formulation technologies, and specialized development and manufacturing capabilities further supports market growth. Additionally, continued innovation in ionizable lipid chemistry, formulation stability, extrahepatic delivery, and scalable manufacturing processes is expected to broaden the clinical and commercial use of LNP-based delivery systems.
The ionizable lipids segment accounted for the largest share of the global LNP raw materials market, by product, in 2025.
By product, the LNP raw materials market is segmented into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials. The ionizable lipids segment accounted for the largest share of the LNP raw materials market in 2025, driven by their critical roles in nucleic acid encapsulation, endosomal escape, and intracellular delivery. Ionizable lipids are central to the performance of LNP formulations for mRNA and siRNA delivery, and their structure strongly influences particle stability, delivery efficiency, biodistribution, and tolerability. Continued investment in next-generation ionizable lipid chemistries to improve potency, biodegradability, and tissue-selective delivery further supports the segment’s leading position.
The mRNA segment is likely to be the fastest-growing molecule type segment in the LNP market.
The global LNP market is segmented by molecule type into siRNA, mRNA, and other molecules. During the forecast period, the mRNA segment is projected to be the fastest-growing, driven by an expanding pipeline of mRNA vaccines and therapeutics across infectious diseases, oncology, protein replacement, and other therapeutic applications. LNPs play a critical role in protecting mRNA from degradation, facilitating cellular uptake, and enabling efficient intracellular delivery. The commercial validation of mRNA-LNP technology, continued investment in next-generation mRNA platforms, and growing clinical development of mRNA-based therapeutics are expected to accelerate demand for LNP raw materials and associated development and manufacturing capabilities worldwide.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=70136984
North America accounted for the largest regional share in the global LNP raw materials & services market in 2025.
The LNP raw materials & services market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2025, North America held the largest share of the global market, driven by a strong concentration of pharmaceutical and biotechnology companies developing mRNA, siRNA, gene-editing, and other nucleic acid therapeutics. The region benefits from advanced biopharmaceutical R&D infrastructure, substantial investment in RNA-based drug development, and specialized lipid suppliers, LNP technology developers, and contract development and manufacturing organizations. Ongoing clinical development and commercialization of LNP-enabled therapeutics, along with investments in domestic biomanufacturing capacity, further support the region’s leading market position.
Key Players
Leading players in the Lipid Nanoparticles companies include Avanti Polar Lipids (Croda International Plc.) (US), Merck KGaA (Germany), Evonik Industries AG (Germany), Nippon Fine Chemical Co., Ltd. (Japan), NOF Corporation (Japan), FUJIFILM Pharmaceuticals, Inc. (FUJIFILM Holdings Corporation) (US), Precision NanoSystems (Canada), Recipharm AB (Sweden), Emergent BioSolutions, Inc. (US), EUROAPI (France), Cayman Chemical (US), CordenPharma (Switzerland), Gattefossé (France), Acuitas Therapeutics (Canada), and IOI Oleo GmbH (Germany).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=70136984v
Lipid Nanoparticles Market – Investment & funding +Merger & Acquisition
Investment Funding Context
The LNP raw materials & services market is seeing increased investment as pharmaceutical, biotechnology, and CDMO companies strengthen capabilities in lipid synthesis, LNP formulation development, targeted delivery, process scale-up, and GMP manufacturing. Recent investments signal a shift from research-scale formulation to integrated clinical and commercial infrastructure. In August 2026, Evonik Industries announced an investment of more than CAD 150 million (EUR 93 million) in a new GMP lipid-based drug-delivery facility in Vancouver, supported by up to CAD 68 million from Canada’s Strategic Response Fund. The facility is expected to more than triple Evonik’s existing production capacity for advanced pharmaceutical products and to expand LNP development, clinical drug-product manufacturing, and quality-control capabilities.
Revenue Shift Context
The LNP market is gradually shifting from a predominantly research-material and formulation-development model toward recurring GMP raw-material supply, clinical manufacturing, and integrated development services. Traditional revenue pools centered on research-grade phospholipids, cholesterol, PEG lipids, ionizable lipids, and laboratory-scale formulation tools remain important; however, customers increasingly require suppliers that can support programs from early formulation screening through scale-up, technology transfer, clinical manufacturing, and commercial supply.
This transition is particularly evident among established suppliers such as Croda/Avanti, Evonik, NOF Corporation, Merck KGaA, and Nippon Fine Chemical, which are expanding higher-value capabilities in pharmaceutical-grade lipids, custom lipid synthesis, novel ionizable lipid libraries, and GMP-compatible supply. For example, Croda’s Avanti Research expanded access to novel ionizable lipids through its 2025 collaboration with Certest and further broadened its advanced lipid portfolio through a 2026 collaboration with NovoArc.
Mergers & Acquisitions
M&A activity in the LNP ecosystem during 2025–2026 has been driven primarily by pharmaceutical companies seeking access to targeted RNA-delivery platforms and next-generation LNP intellectual property, rather than by conventional consolidation among bulk lipid suppliers. Buyers are prioritizing technologies that enable tissue-specific or extrahepatic delivery and accelerate the development of in vivo genetic medicines.
LIPID NANOPARTICLES MARKET: MERGERS & ACQUISITIONS, JANUARY 2025–AUGUST 2026
Month & Year | Deal Type | Company 1 | Company 2 | Description |
August 2025 | Acquisition | AbbVie (US) | Capstan Therapeutics (US) | AbbVie completed its acquisition of Capstan Therapeutics for up to USD 2.1 billion, gaining Capstan’s proprietary targeted LNP platform for delivering RNA payloads and its Phase 1 CPTX2309 in vivo CAR-T candidate. |
December 2025 | Acquisition | XOMA Royalty (US) | Generation Bio (US) | XOMA Royalty agreed to acquire Generation Bio, adding its cell-targeted LNP (ctLNP) technology and associated collaboration economics to its genetic-medicine portfolio. |
July 2026 | Acquisition | Valerio Therapeutics (France) | Etherna Immunotherapies (Belgium) | Valerio signed a binding offer to acquire Etherna for approximately USD 34.20 million (EUR 30 million) enterprise value, combining targeted delivery capabilities with Etherna’s proprietary mRNA and customizable LNP platform. |
Company Revenue Share Details
The LNP raw materials market is relatively consolidated, with Avanti Polar Lipids (Croda International), Merck KGaA, NOF Corporation, and Nippon Fine Chemical collectively estimated to account for approximately 70–75% of the market based on the current study framework. These companies benefit from established pharmaceutical-lipid manufacturing capabilities, broad portfolios spanning phospholipids, PEGylated lipids, neutral lipids and ionizable lipids, and the ability to supply materials across research, clinical, and GMP applications.
Competition is increasingly shifting beyond conventional lipid breadth toward proprietary ionizable lipid chemistry, high-purity GMP manufacturing, custom lipid synthesis, scalable supply, and formulation-development support. Croda/Avanti continues to broaden its ionizable-lipid portfolio through external collaborations, while NOF leverages its established phospholipid and PEG-lipid capabilities and Evonik continues to expand both lipid manufacturing and integrated LNP development infrastructure.
Browse Adjacent Market: Biotechnology Market Research Reports &Consulting
See More Latest Biotechnology Reports:
Pharmaceutical Drug Delivery Market By Administration Route (Oral, Injectable, Topical, Ocular, Nasal, Transmucosal & Implantable, Pulmonary, Transdermal Patch), Application (Cancer, Diabetes, Cardiovascular), Facility of Use – Global Forecast to 2031
Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) – Global Forecast to 2029
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/lipid-nanoparticles-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/lipid-nanoparticles.asp
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/lipid-nanoparticles-market-worth-395-0-million-by-2031—exclusive-report-by-marketsandmarkets-302913166.html
Read the orginal article: undefined
